ReviewJAC-antimicrobial resistance2026
Recent advancements in artificial intelligence applications for the mitigation of antimicrobial resistance: challenges and opportunities.
Review in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) poses a significant global public health threat, and efforts to mitigate it have been aided by artificial intelligence (AI) methods. Key areas of applications include rapid diagnostics, drug discovery and repurposing, surveillance and predictive modelling, and antibiotic stewardship. This review aims to summarize key literature on AI applications for mitigating AMR including original research articles from PubMed and Scopus published from October 2024 to 2025 to summarize and find out the way ahead for successful application of AI. The key search terms included were AMR, AI and applications such as diagnostics, drug discovery and repurposing, surveillance, predictive modelling and stewardship. The data used for these applications, the techniques applied and the predictive targets have undergone significant expansion, along with the focus on model deployment, external validation and model interpretability. Although more complex models, such as neural networks and transformers, have been experimented with, classical machine learning (ML) models still dominate the AMR prediction space, while large language models are also being tested for prediction, as well as antibiotic stewardship. For drug discovery, data mining for antimicrobial peptides from different sources is a major application. Predictive modelling using next-generation sequencing data has been the most studied. The application of AI/ML to large and complex data from multiple sources could provide a promising arena for developing clinically translational tools. With more data availability, regulatory measures, real-world validation and transparency, there is scope for responsibly integrating innovative technology into clinical practice.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.